Navigation Links
Pathwork Diagnostics Launches Version of Its Tissue of Origin Test for FFPE Specimens
Date:1/13/2009

New Version Increases Physician Access

SUNNYVALE, Calif., Jan. 13 /PRNewswire/ -- Pathwork Diagnostics, Inc., launched today an additional version of the Pathwork(R) Tissue of Origin Test that has the capability of analyzing formalin-fixed, paraffin-embedded (FFPE) tissue specimens. This molecular diagnostic test, which aids in the diagnosis of tumors with uncertain origins, is now available as a service through the CLIA-certified Pathwork Diagnostics Laboratory.

"The capability to work with FFPE specimens will enable our test to be more broadly utilized by oncologists and pathologists," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "Due to the RNA degradation that occurs in FFPE specimens, generating robust and reproducible data for many genes simultaneously was a significant challenge. Maintaining the high level of robust and reliable performance for the FFPE version of the test was an outstanding technical accomplishment by the company."

To determine the tumor's origin, the Pathwork Tissue of Origin Test uses microarray technology to measure the expression pattern, comprising more than 1,500 genes, in a tumor with an uncertain origin and compares it to expression patterns of a panel of 15 known tumor types, representing 90 percent of all solid tumors and 58 morphologies overall. In the clinical validation study utilizing FFPE tumor specimens, the test demonstrated 89% positive percent agreement (akin to sensitivity) with available diagnoses and greater than 99% negative percent agreement (akin to specificity).(1) This statistically significant study consisted of 352 metastatic, poorly differentiated and undifferentiated tumors that had been identified as one of the 15 tumor types on the panel using existing methods.

The American Cancer Society estimates that there are 1.4 million new cancer diagnoses annually in the United States. Of these new cases, up to 10 percent are of tumor types not readily classifiable in the course of the initial diagnostic workup.(2) Tumors with uncertain origins are among the most frustrating for physicians and place a disproportionate burden on patients, healthcare professionals, and the healthcare system.

"Now that the Pathwork Tissue of Origin Test works with FFPE specimens, it will be more easily available for pathologists to utilize," said Dr. Larry Weiss, Chair, Division of Pathology, City of Hope. "When there is uncertainty about a tumor's origin, the Tissue of Origin Test holds the promise of delivering unique data not available through other methods, filling the information gap with accurate, objective, actionable information that may allow a patient's physician to make treatment decisions with greater confidence."

By utilizing the Tissue of Origin Test, physicians will be able to use objective criteria to identify the primary site of a tumor's origin, the first step in beginning standard-of-care, tumor-specific therapy per National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines. Targeting therapy to specific tumor types can also allow patients to avoid the toxicity of broader, and in some cases, ineffective chemotherapy. The test may also allow physicians to arrive at a diagnosis sooner, which can benefit cancer patients by enabling treatment to begin more quickly and allowing patients to enroll in and benefit from appropriate clinical trials.

With today's announcement, the Pathwork(R) Diagnostics Laboratory is now able to process and analyze both FFPE and frozen tissue specimens. Upon specimen receipt, Pathwork runs the microarray test on the specimens, and a staff pathologist interprets the test results and provides a comprehensive clinical report to the physician. Pathwork will seek FDA clearance for the FFPE version of the Tissue of Origin Test in an in vitro diagnostic (IVD) kit format so that pathologists can run the test in their own clinical laboratories.

"The FFPE version of the test will utilize the Pathchip(R) microarray, which runs on the proven Affymetrix GeneChip(R) System 3000Dx," said Kevin King, Affymetrix President and Chief Executive Officer. "We're proud to partner with Pathwork and congratulate them on being our first partner to validate the Affymetrix platform for FFPE diagnostic tissue specimens. We are excited about the potential for this product and look forward to working collaboratively with Pathwork as they build their diagnostic product line based on the Affymetrix platform."

About Pathwork Diagnostics

Pathwork Diagnostics, Inc., based in Sunnyvale, Calif., develops and commercializes high-value molecular diagnostics for oncology. The company's first test to market - the Pathwork(R) Tissue of Origin Test - utilizes proprietary analytics and a companion Pathchip(R) microarray, which runs on the proven Affymetrix GeneChip(R) System. For more information, call 1.877.808.0006 or visit www.pathworkdx.com.

Copyright (C) 2009 Pathwork Diagnostics, Inc. All rights reserved. Pathwork, Pathchip, Pathwork Diagnostics, and the Pathwork Diagnostics and the Pathwork Tissue of Origin logos are trademarks or registered trademarks of Pathwork Diagnostics, Inc. Other names may be the trademarks of their respective owners.

(1) Date on file. Pathwork Diagnostics: 2008.

(2) Pathwork market research data on file. Pathwork Diagnostics: 2008.

    CONTACT: Scott Shadiow
             415.515.0786
             media@pathworkdx.com


'/>"/>
SOURCE Pathwork Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pathwork Diagnostics Collaborates With Guys and St Thomas on Tissue of Origin Test Validation in the UK
2. Pathwork Tissue of Origin Test Shows Potential to Aid in the Diagnosis of Cancer of Unknown Primary
3. Studies Investigate Diagnostic Performance and Reproducibility of Pathwork Diagnostics Tissue of Origin Test
4. Quest Diagnostics to Release Fourth Quarter and Full Year 2008 Financial Results
5. HistoRx Names Kate Adams Vice President, Diagnostics Marketing and Retains Steve Chubb as Strategic Advisor
6. Fujirebio Diagnostics and Roche Diagnostics Sign Agreement for New Ovarian Cancer Test
7. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
8. Development of Novel Assays Vital for the European Immunoassay Diagnostics Market
9. Quest Diagnostics to Speak at the 20th Annual Piper Jaffray Healthcare Conference
10. VIDA Diagnostics Gains FDA Approval for Comprehensive Lung Analysis Software
11. Quest Diagnostics to Speak at the 2008 Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... The VA Maryland ... collaborating on a research project focused on multiple sclerosis (MS). Led by Christopher ... nanotechnology to control the disease without compromising normal immune function that often occurs ...
(Date:1/18/2017)... West Palm Beach, FL (PRWEB) , ... January 18, 2017 , ... ... April as a fund raiser for Smile Train, an international charity that provides free ... is a hobby of mine and in the past I have run to support ...
(Date:1/18/2017)... ... January 18, 2017 , ... At Hallmark Nameplate, their commitment to quality ... achieved certification to ISO 13485. This certification is another way they are making constant ... and services that they need. , The ISO 13485 Certification is a major accomplishment ...
(Date:1/18/2017)... ... January 18, 2017 , ... The Hear the ... project with the donation of cochlear implants. In February 2017, the first three ... a fair chance of leading an independent life. This engagement builds on the ...
(Date:1/17/2017)... , ... January 17, 2017 , ... January is National Stalking Awareness Month ... to lurk in the corners and commit the crime of stalking, a very real danger ... addiction, an often overlooked factor in stalking and other crimes. , “Stalking: know it. Name ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... , Jan. 18, 2017  Eisai Inc., ... announced today that it is participating in Access ... non-communicable diseases (NCDs) prevention, treatment and care in ... Accelerated is the first multi-stakeholder, international initiative in ... pharmaceutical companies, including Eisai, in collaboration with the ...
(Date:1/18/2017)... NEW YORK , January 18, 2017 ... perception of people regarding the use of cannabis both for ... not only are more Americans open to the use of ... and financial sectors. According to Arcview Market Research, the North ... 2016, up 30% from the previous year. The research projects ...
(Date:1/17/2017)... Jan. 17, 2017 Precision medicine is ... the treatment of disease. The approach allows doctors ... a therapy. The approach studies the individual profile ... and environment. In January 2015, Precision Medicine Initiative ... all diseases with more than one million volunteers. ...
Breaking Medicine Technology: